Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.63 |
| ▸ | CA2 | P00918 | 6/20 | 0.63 |
| ▸ | CA12 | O43570 | 5/20 | 0.63 |
| ▸ | CA7 | P43166 | 5/20 | 0.63 |
| ▸ | CA9 | Q16790 | 5/20 | 0.63 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | XDH | P47989 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ULK1 | O75385 | 1/20 | 0.44 |
| ▸ | KAT6A | Q92794 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1107694 | 0.89 | CA1 (0.50) | CA1CA2CA12CA7CA9 | |
| SCHEMBL1791405 | 0.89 | CA1 (0.50) | CA1CA2CA12CA7CA9 | |
| SCHEMBL30744997 | 0.85 | CA1 (0.61) | CA1CA2CA12CA7CA9 | |
| SCHEMBL20944347 | 0.85 | CA1 (0.61) | CA1CA2CA12CA7CA9 | |
| SCHEMBL12774009 | 0.84 | CA12 (0.56) | CA1CA2CA12CA7CA9 | |
| SCHEMBL1042110 | 0.84 | CA12 (0.56) | CA1CA2CA12CA7CA9 | |
| SCHEMBL9072499 | 0.84 | CA12 (0.56) | CA1CA2CA12CA7CA9 | |
| SCHEMBL2662774 | 0.84 | CA12 (0.56) | CA1CA2CA12CA7CA9 | |
| SCHEMBL320646 | 0.83 | CA12 (0.54) | CA1CA2CA12CA7CA9 | |
| SCHEMBL2088534 | 0.83 | CA12 (0.54) | CA1CA2CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10174062-B2 | Activators of glucokinase | METABASIS THERAPEUTICS, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-10174062-B2 | Activators of glucokinase | METABASIS THERAPEUTICS, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-10005805-B2 | — | — | 2018-06-26 | — | — | US | disclosed |
| US-10005805-B2 | — | — | 2018-06-26 | — | — | US | disclosed |
| US-10005805-B2 | — | — | 2018-06-26 | — | — | US | disclosed |
| EP-1600442-B1 | HETEROARYLCARBAMOYLBENZENE DERIVATIVE | MSD KK (JP) | 2018-01-17 | — | — | EP | disclosed |
| US-20170096440-A1 | NOVEL ACTIVATORS OF GLUCOKINASE | METABASIS THERAPEUTICS, INC. | 2017-04-06 | — | — | US | disclosed |
| US-20170096440-A1 | NOVEL ACTIVATORS OF GLUCOKINASE | METABASIS THERAPEUTICS, INC. | 2017-04-06 | — | — | US | disclosed |
| US-20170096440-A1 | NOVEL ACTIVATORS OF GLUCOKINASE | METABASIS THERAPEUTICS, INC. | 2017-04-06 | — | — | US | disclosed |
| US-9522926-B2 | Activators of glucokinase | METABASIS THERAPEUTICS, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| WO-2005056530-A1 | BENZOYL AMINO PYRIDYL CARBOXYLIC ACID DERIVATIVES USEFUL AS GLUCOKINASE (GLK) ACTIVATORS | ASTRAZENECA AB (SE) | 2005-06-23 | — | — | WO | disclosed |
| WO-2005054200-A1 | BENZOYL AMINO PYRIDYL CARBOXYLIC ACID DERIVATIVES USEFUL AS GLUCOKINASE (GLK) ACTIVATORS | ASTRAZENECA AB (SE) | 2005-06-16 | — | — | WO | disclosed |
| EP-1529530-A1 | Compounds affecting glucokinase | AstraZeneca AB (SE) | 2005-05-11 | — | — | EP | disclosed |
| US-20050080106-A1 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2005-04-14 | — | — | US | disclosed |
| US-20040214868-A1 | Amino nicotinate derivatives as glucokinase (GLK) modulators | ASTRAZENECA AB (SE) | 2004-10-28 | — | — | US | disclosed |
| EP-1420784-A1 | COMPOUNDS EFFECTING GLUCOKINASE | Astrazeneca AB (SE) | 2004-05-26 | — | — | EP | disclosed |
| EP-1404335-A1 | AMINO NICOTINATE DERIVATIVES AS GLUCOKINASE (GLK) MODULATORS | Astrazeneca AB (SE) | 2004-04-07 | — | — | EP | disclosed |
| WO-2003015774-A1 | COMPOUNDS EFFECTING GLUCOKINASE | ASTRAZENECA AB (SE) | 2003-02-27 | — | — | WO | disclosed |
| WO-2003015774-A1 | COMPOUNDS EFFECTING GLUCOKINASE | ASTRAZENECA AB (SE) | 2003-02-27 | — | — | WO | disclosed |
| WO-2003000267-A1 | AMINO NICOTINATE DERIVATIVES AS GLUCOKINASE (GLK) MODULATORS | ASTRAZENECA AB (SE) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005805-B2 | — | GCKR, GCK, HK1 | CA1 1336/4885CA2 316/4885CA12 2318/4885 |
| US-20050080106-A1 | Compounds effecting glucokinase | GCKR, GCK, SLC5A2 | CA1 1388/4885CA2 540/4885CA12 2139/4885 |
| US-20040214868-A1 | Amino nicotinate derivatives as glucokinase (GLK) modulators | GCK, GCKR, NADK | CA1 3192/4885CA2 1209/4885CA12 4001/4885 |
| US-20170096440-A1 | NOVEL ACTIVATORS OF GLUCOKINASE | GCKR, GCK, HK1 | CA1 2103/4885CA2 532/4885CA12 3508/4885 |
| US-10174062-B2 | Activators of glucokinase | GCKR, GCK, HK1 | CA1 1905/4885CA2 561/4885CA12 3411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.